Frances Rees

Summary

Country: UK

Publications

  1. ncbi request reprint Compliance with NICE guidance on the use of anti-TNFalpha agents in ankylosing spondylitis: an east and west Midlands regional audit
    Frances Rees
    Nottingham University Hospitals NHS Trust, Nottingham
    Clin Med 12:324-7. 2012
  2. doi request reprint Distribution of finger nodes and their association with underlying radiographic features of osteoarthritis
    Frances Rees
    University of Nottingham, Nottingham, UK
    Arthritis Care Res (Hoboken) 64:533-8. 2012
  3. doi request reprint Long-term follow-up of different refractory systemic vasculitides treated with rituximab
    Frances Rees
    Nottingham University Hospitals NHS Trust, Queen s Medical Centre Campus, Derby Road, Nottingham, UK
    Clin Rheumatol 30:1241-5. 2011

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Compliance with NICE guidance on the use of anti-TNFalpha agents in ankylosing spondylitis: an east and west Midlands regional audit
    Frances Rees
    Nottingham University Hospitals NHS Trust, Nottingham
    Clin Med 12:324-7. 2012
    ..Based on our audit, clinical capacity, and clinical or patient choice might be influencing the suboptimal adherence seen in assessment timing suggested by NICE guidelines relating to the use of anti-TNFalpha in treating patients with AS...
  2. doi request reprint Distribution of finger nodes and their association with underlying radiographic features of osteoarthritis
    Frances Rees
    University of Nottingham, Nottingham, UK
    Arthritis Care Res (Hoboken) 64:533-8. 2012
    ....
  3. doi request reprint Long-term follow-up of different refractory systemic vasculitides treated with rituximab
    Frances Rees
    Nottingham University Hospitals NHS Trust, Queen s Medical Centre Campus, Derby Road, Nottingham, UK
    Clin Rheumatol 30:1241-5. 2011
    ..These results provide further evidence that RTX is an effective induction agent in systemic vasculitis. The optimal and long-term outcome of re-treatment remains to be defined...